Published in J Gastroenterol on February 07, 2012
Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr (2015) 1.50
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol (2015) 1.06
Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol (2013) 0.99
Early growth response protein-1 mediates lipotoxicity-associated placental inflammation: role in maternal obesity. Am J Physiol Endocrinol Metab (2013) 0.96
Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care (2012) 0.96
Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks. Int J Mol Sci (2013) 0.93
Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol (2014) 0.92
CD44 plays a critical role in regulating diet-induced adipose inflammation, hepatic steatosis, and insulin resistance. PLoS One (2013) 0.92
Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. Pediatr Res (2014) 0.90
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol (2015) 0.89
CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol (2013) 0.87
Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice. J Obes (2013) 0.87
Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. PLoS One (2013) 0.86
LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget (2015) 0.84
Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance? PLoS One (2015) 0.82
Tumor necrosis factor-inducible gene 6 promotes liver regeneration in mice with acute liver injury. Stem Cell Res Ther (2015) 0.82
Effect of chronic psychosocial stress on nonalcoholic steatohepatitis in mice. Int J Clin Exp Pathol (2013) 0.82
Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One (2013) 0.82
The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol (2014) 0.81
Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB J (2014) 0.81
Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat. Eur J Med Res (2013) 0.80
Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol (2014) 0.79
Does vitamin C deficiency promote fatty liver disease development? Nutrients (2014) 0.78
Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS One (2016) 0.78
Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci (2014) 0.78
Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Hepatobiliary Surg Nutr (2015) 0.77
GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. World J Gastroenterol (2014) 0.76
L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease. Lipids Health Dis (2014) 0.75
Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin. J Biol Chem (2016) 0.75
Attrition of Hepatic Damage Inflicted by Angiotensin II with α-Tocopherol and β-Carotene in Experimental Apolipoprotein E Knock-out Mice. Sci Rep (2015) 0.75
Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) (2014) 0.75
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol (2016) 0.75
Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. Biochim Biophys Acta (2015) 0.75
Lipoic Acid prevents the changes of intracellular lipid partitioning by free Fatty Acid. Gut Liver (2013) 0.75
A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Biomed Res Int (2017) 0.75
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int J Mol Sci (2017) 0.75
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell (2006) 10.18
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 9.77
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest (2006) 9.49
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science (2006) 5.52
cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun (1996) 5.40
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest (2008) 5.27
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (2010) 4.76
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med (2006) 4.36
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes (2007) 4.28
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A (1997) 3.79
Toll-like receptors and adaptor molecules in liver disease: update. Hepatology (2008) 3.72
NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest (2003) 3.69
Regulation of fasted blood glucose by resistin. Science (2004) 3.54
Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest (2006) 3.44
Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol (2010) 3.36
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol (2007) 3.23
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol (2003) 3.04
Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology (2002) 2.97
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2010) 2.95
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology (2006) 2.77
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem (2001) 2.70
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (2001) 2.69
Leptin in immunology. J Immunol (2005) 2.62
Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem (2001) 2.58
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol (2002) 2.46
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes (2001) 2.43
Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology (2003) 2.38
Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.35
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia (2006) 2.27
Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol (2003) 2.27
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology (2002) 2.26
Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis (2009) 2.22
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 2.19
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology (2000) 2.09
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol (2009) 2.06
The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med (1999) 2.05
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Hepatic steatosis: innocent bystander or guilty party? Hepatology (1998) 1.94
Peroxisomal lipid metabolism. Annu Rev Nutr (1994) 1.93
In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol (2002) 1.86
Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol (2002) 1.86
Mitochondrial beta-oxidation. Eur J Biochem (2004) 1.85
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J (2008) 1.85
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology (1996) 1.83
Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev (2008) 1.82
Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol (2009) 1.80
Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol (2001) 1.79
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology (2009) 1.79
A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol (2006) 1.70
The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med (2001) 1.69
Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol (2008) 1.66
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis (2009) 1.58
Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology (2010) 1.58
Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology (2008) 1.53
Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem (2005) 1.53
Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut (2005) 1.53
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs (2009) 1.42
Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des (2010) 1.41
The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol (2004) 1.36
Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.33
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.33
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun (2009) 1.41
MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut (2012) 1.40
Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun (2011) 1.39
Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis. Lab Invest (2004) 1.38
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut (2006) 1.31
Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology (2006) 1.31
BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol (2005) 1.28
Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology (2003) 1.24
Macrophage scavenger receptor down-regulates mycobacterial cord factor-induced proinflammatory cytokine production by alveolar and hepatic macrophages. Microb Pathog (2006) 1.20
Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-β-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol (2011) 1.19
Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem (2003) 1.13
Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'? J Gastroenterol (2013) 1.08
Identification of vitamin A-free cells in a stellate cell-enriched fraction of normal rat liver as myofibroblasts. Histochem Cell Biol (2006) 1.08
Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. Hepatology (2003) 1.08
Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology (2005) 1.06
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol (2012) 1.04
Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair (2012) 1.02
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol (2011) 1.02
Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb (2009) 1.02
Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice. Am J Pathol (2011) 1.02
Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta. Gastroenterology (2002) 1.01
Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. J Gastroenterol (2010) 1.00
Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci (2014) 0.99
Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. Lab Invest (2009) 0.99
Structural characterization of the proximal and distal histidine environment of cytoglobin and neuroglobin. Biochemistry (2005) 0.99
Characterization of the heme environmental structure of cytoglobin, a fourth globin in humans. Biochemistry (2003) 0.98
Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol (2005) 0.98
Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. World J Gastroenterol (2006) 0.97
Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol (2011) 0.97
Structural basis of human cytoglobin for ligand binding. J Mol Biol (2004) 0.96
Interferon-gamma-mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in mice. Hepatology (2013) 0.96
Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas (2009) 0.96
Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol (2009) 0.94
The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer (2013) 0.94
Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res (2006) 0.94
Typing of hepatic nonparenchymal cells using fibulin-2 and cytoglobin/STAP as liver fibrogenesis-related markers. Histochem Cell Biol (2004) 0.94
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther (2007) 0.93
Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas (2010) 0.93
Hepatic sinusoidal cells in health and disease: update from the 14th International Symposium. Liver Int (2009) 0.93
A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol (2010) 0.92
HLA class II associated with outcomes of hepatitis B and C infections. World J Gastroenterol (2013) 0.92
Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol (2007) 0.92
Characterization of human stellate cell activation-associated protein and its expression in human liver. Biochim Biophys Acta (2002) 0.92
Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med (2008) 0.91
Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol (2009) 0.90
Cytoglobin, a novel member of the globin family, protects kidney fibroblasts against oxidative stress under ischemic conditions. Am J Pathol (2010) 0.90
Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol (2013) 0.90
Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res (2010) 0.90
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther (2014) 0.89
Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis. Oncology (2013) 0.89
Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res (2013) 0.88
Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. J Med Virol (2005) 0.88
Regulation of cultured rat hepatocyte proliferation by stellate cells. J Hepatol (2002) 0.88
Fascin, a novel marker of human hepatic stellate cells, may regulate their proliferation, migration, and collagen gene expression through the FAK-PI3K-Akt pathway. Lab Invest (2011) 0.87
Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis. Virchows Arch (2002) 0.87
Rho kinases regulate endothelial invasion and migration during valvuloseptal endocardial cushion tissue formation. Dev Dyn (2006) 0.87
Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. Hepatol Res (2011) 0.86
Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One (2013) 0.86
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther (2014) 0.85
Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res (2003) 0.85
Involvement of Galectin-1 and Galectin-3 in Proliferation and Migration of Rat Hepatic Stellate Cells in Culture. Comp Hepatol (2004) 0.85
Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatol Res (2012) 0.85
Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol (2005) 0.84
Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. J Hepatol (2006) 0.84
A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status. Liver Transpl (2009) 0.84
Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med (2007) 0.84
A case of primary small cell carcinoma of the liver that was treated with chemotherapy. Hepatol Int (2008) 0.84
Sulfur-containing amino acids attenuate the development of liver fibrosis in rats through down-regulation of stellate cell activation. J Hepatol (2004) 0.83
Carbenoxolone inhibits DNA synthesis and collagen gene expression in rat hepatic stellate cells in culture. J Hepatol (2003) 0.83
Thioredoxin prevents thioacetamide-induced acute hepatitis. Comp Hepatol (2004) 0.83
Inhibition of the activation of hepatic stellate cells by arundic acid via the induction of cytoglobin. Biochem Biophys Res Commun (2012) 0.83
Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol (2014) 0.83
Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res (2014) 0.82
A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. Intern Med (2013) 0.82
Attenuation of acute and chronic liver injury in rats by iron-deficient diet. Am J Physiol Regul Integr Comp Physiol (2007) 0.82
High-resolution structure of human cytoglobin: identification of extra N- and C-termini and a new dimerization mode. Acta Crystallogr D Biol Crystallogr (2006) 0.81
Pepstatin A attenuates the inhibitory effect of N-acetyl-L-cysteine on proliferation of hepatic myofibroblasts (stellate cells). Eur J Pharmacol (2002) 0.81
Rho kinase inhibitor Y27632 affects initial heart myofibrillogenesis in cultured chick blastoderm. Dev Dyn (2007) 0.81
Noninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree. Oncology (2014) 0.80
Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol (2012) 0.80
Effect of S-adenosyl-L-methionine on the activation, proliferation and contraction of hepatic stellate cells. Eur J Pharmacol (2005) 0.80
Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int (2007) 0.80
High prevalence of gastroesophageal reflux symptoms in patients with non-alcoholic fatty liver disease associated with serum levels of triglyceride and cholesterol but not simple visceral obesity. Digestion (2012) 0.80
Emerging antiviral drugs for hepatitis C virus. Rev Recent Clin Trials (2009) 0.79
Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res (2013) 0.79
A case of sclerosing cholangitis with autoimmune pancreatitis evaluated by FDG-PET. Ann Nucl Med (2007) 0.79
Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. World J Gastroenterol (2012) 0.79
[Rabbit model for the study of human NASH]. Nihon Rinsho (2006) 0.78
[Drug-induced liver injury caused by an herbal medicine, bofu-tsu-sho-san]. Nihon Shokakibyo Gakkai Zasshi (2008) 0.78
N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis. Glycobiology (2012) 0.78
[Tumor lysis syndrome after transarterial embolization for hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi (2013) 0.78
Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. Liver Int (2008) 0.78
Induction of tropomyosin during hepatic stellate cell activation and the progression of liver fibrosis. Hepatol Int (2008) 0.78
Cancer serum proteomics in gastroenterology. Gastroenterology (2006) 0.78